Skip to main content

What the FDA labels say about taking them together

Midazolam and palbociclib

Palbociclib's FDA label of July 2, 2026 names midazolam in its drug interactions section; the midazolam labels PlainMeds reads (4) do not name palbociclib. The palbociclib label: “Altered by Palbociclib Coadministration of midazolam with multiple doses of IBRANCE increased the midazolam plasma exposure by 61%, in healthy subjects, compared to administration of midazolam alone.”

Check it at the source: the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the midazolam label say about palbociclib?

Midazolam's label (effective January 1, 2024) and its 3 other brand-application labels do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed

What does the palbociclib label say about midazolam?

Palbociclib label, drug interactions

Altered by Palbociclib Coadministration of midazolam with multiple doses of IBRANCE increased the midazolam plasma exposure by 61%, in healthy subjects, compared to administration of midazolam alone.

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

22Midazolam generic labelers
0Palbociclib generic labelers
MidazolamPalbociclib
Labeled forn/aBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$0.233 per mL 2 mg/2 mL vialn/a
Shortage nowIn shortageA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?